The Rag2 -/-mouse lacks all B and T cell function as a result of homozygous deletion of the Recombinase Activating Gene 2 (Rag2). Cells from a clipping of the mouse tail were cultured briefly. Using micromanipulation, the nucleus of a tail-tip cell was removed and inserted into a donor egg, whose own nucleus had been removed by micromanipulation. The reconstructed zygote underwent cleavage and development to blastocyst stage, after which the cells of the inner cell mass were removed and placed in culture, forming an ES cell line with genetic equivalence to the Rag2 -/-mouse. One of the two defective Rag2 alleles was replaced with an intact copy by homologous recombination, generating a repaired ntES Rag2+/-cell line. These cells were differentiated in vitro into hematopoietic stem cells, and used to transplant irradiated immune-deficient Rag2 -/-recipients. Engrafted mice showed restoration of T and B cell populations and production of serum immunoglobulin, demonstrating the feasibility of combined gene and cell therapy (therapeutic cloning; Rideout et al 27 ).
Melo et al Figure 1. Structure of the p210
Bcr-Abl fusion protein and mechanisms of leukemogenesis.
Some of the important functional domains on the Bcr and Abl moieties are shown: in Bcr, the dimerization domain (DD), the Y177 autophosphorylation site for adaptor protein binding, the phosphoserine/phosphothreoninerich sequences(P-S/T) on the SH2-binding domain, and the region homologous to Rho guanidine nucleotide exchange factors (Rho-GEF); in Abl, the Src-homology SH2 and SH3 regulatory domains, the tyrosine kinase (SH1) domain where binding to ATP and substrate takes place, 1 of the 3 nuclear localization signal (NLS), 1 of 3 DNA-binding, a nuclear export signal (NES) and 1 of 2 actin-binding domains. Disruption of the tightly regulated tyrosine kinase activity of Abl by dimerization of the protein effected by BCR first exon sequences (indicated by the arrow) results cellular responses that characterize the leukemic phenotype. 
Nagel Figure 7 (in Atweh et al

Melo et al Figure 2. Targets for molecular therapy.
Each target is numbered and marked with a "target" sign. 1. The SH1 or tyrosine kinase domain of Bcr-Abl: its activity can be inhibited by signal transduction inhibitors, such as imatinib mesylate or adaphostin. 2. The dimerization (coiled-coil) domain of Bcr-Abl: deletion/ mutation or blocking of this domain with peptides that prevent oligomerization renders Bcr-Abl nontransforming. 3. Heat-shock protein 90 (Hsp90): Hsp90 functions as chaperone that maintains the stability of the Bcr-Abl protein; antagonists of Hsp90, such as geldanamycin, destabilize Bcr-Abl and promote its proteasomal degradation. 4. BCR-ABL mRNA: synthesis of the Bcr-Abl oncoprotein may be suppressed by inhibiting BCR-ABL mRNA by either antisense oligonucleotides, siRNA molecules, ribozymes or DNAzymes. 5. The SH3 domains of the adapter proteins Grb2 or CrkL: synthetic peptides that bind to these domains "uncouple" Bcr-Abl from downstream signaling pathways. 6. Farnesyl transferase: inhibitors of farnesyl transferase suppress Ras signaling by preventing the attachment of a farnesyl group to Ras; farnesyl groups are essential for the normal functioning of Ras since they tether these G-proteins to the plasma membrane. 7. Mek (MAPK or ERK Kinase): Bcr-Abl constitutively activates the Ras-Raf-Mek-Erk pathway; Mek inhibitors may be useful for inhibiting this mitogenic cascade 8. PI-3 kinase: PI-3 kinase associates with Bcr-Abl and undergoes activation as a result of tyrosine phosphorylation; PI-3 kinase cell signaling may be inhibited with compounds such as wortmannin or LY294002, resulting in apoptosis by activation of Bad (proapoptotic) via Akt and its dissociation from Bcl-X L (antiapoptotic). 9. mTOR: this PI-3 kinase effector and two of its substrates, ribosomal protein S6 and 4E-BP1, are constitutively phosphorylated in a Bcr-Abl-dependent manner; the pathway can be inhibited by rapamycin. Figure 3 . Estimated log-reduction of BCR-ABL transcripts after 12 months of first-line therapy by treatment arm.
Melo et al
Whereas an estimated 39% of all patients on imatinib achieved a ≥ 3 log reduction in BCR-ABL/BCR ratio at 12 months (20% had a ≥ 3 to < 4 log reduction, 19% had a ≥ 4 log reduction), only 2% of patients on interferon (IFN) + cytarabine (Ara-C) achieved this molecular response within 12 months (P < .001).
Braziel Figure 1. An example of a real time quantitative fluorescence RT-PCR assay (Q-RT-PCR) for detection of minimal residual disease (MRD) in chronic myelogenous leukemia (CML).
(A) The graph shows a typical standard curve, generated by Q-RT-PCR of a series of serial dilutions of a BCR/ABL (+) cell line. BCR/ ABL transcripts in RNA from clinical samples are quantitated by comparison to this standard curve. p210 and p190 BCR/ABL transcripts, in both cell line standards and patient samples, are normalized to G6PDH housekeeping gene. The fluorescence signal generated during the PCR process is proportional to the starting quantity of BCR/ABL template, and is detected by a fluorimeter in the instrument. The PCR reaction is monitored in real time, during the geometric phase of the reaction; data from the linear and plateau phases are not used. The standard test will detect 1 BCR/ABL (+) cell in 10 5 normal cells. (B) Increased analytical sensitivity of 1 (+) cell in 10 6-7 normal cells can be obtained by concentration of sample RNA used in the analysis.
Shipp Figure 3 (in Braziel et al). Oligonucleotide versus cDNA microarrays.
Reprinted with permission from Ramaswamy S, Golub TR. DNA microarrays in clinical oncology. J Clin Oncol. 2002; 20:1932 .
Shipp Figure 4 (in Braziel et al). Unsupervised versus supervised learning.
Green Figure 1 (in Carmel et al). Major pathways for remethylation and transsulfuration of homocysteine and related metabolic pathways, showing substrates, cofactors and enzymes.
Abbreviations: MS, methionine synthase; CbS, cystathionine beta synthase; MTHFR, methylenetetrahydrofolate reductase; DHFR, dihydrofolate reductase; TS, thymidylate synthase; THF, tetrahydrofolate.
DiPersio Figure 3 (in Cottler-Fox et al). Effect of granulocyte colony-stimulating factor (G-CSF) on mobilization of leukocyte subsets in normal donors (n = 100).
Lapidot Figure 1 (in Cottler-Fox et al). A model for stress-induced mobilization.
DNA-damaging chemotherapy drugs such as Cy and inflammatory cytokines such as G-CSF first induce a transient increase in SDF-1 levels within the BM as part of the alarm situation. Next, G-CSF directly and indirectly (via secretion of IL-8, SDF-1, and other factors) triggers neutrophils to proliferate and release proteases such as elastase, cathepsin G, and proteinase 3. In parallel, proliferation and activation of osteoclasts, which release the mobilizing chemokine IL-8 and secrete MMP-9 in response to SDF-1 stimulation, take place. The massive inflammatory proteolytic enzyme activity leads to degradation of stem cell anchorage and retention signals (VCAM-1 and SDF-1), inactivation of G-CSF, and remodeling of the BM extracellular matrix. MMP-9 mediates shedding of membrane-bound SCF, which together with proteinase 3 induces progenitor cell proliferation and CXCR4 upregulation, followed by partial inactivation of CXCR4 and c-kit by the proteolytic machinery. These sequential events, which are repeated and intensified after each cycle of G-CSF stimulation, orchestrate the egress of progenitors from the BM into the circulation.
Abbreviations: BM, bone marrow; CXCR4, CXC chemokine receptor 4; Cy, cyclophosphamide; G-CSF, granulocyte colony-stimulating factor; IL-8, interleukin-8; MMP-9, matrix metalloproteinase 9; SCF, stem cell factor; SDF-1, stromal-derived cell factor-1; VCAM-1, vascular cell adhesion molecule 1.
Aird Figure 1 (in Warkentin et al). Schematic of interactions between platelets and endothelial cells.
Shown are three endothelial cells, a number of small platelets, and a representative monocyte. Vertical arrows indicate soluble molecules that are released by one cell type and signal in the other. Curved and horizontal arrows indicate platelet-leukocyte cross talk and shear stress, respectively, both of which may impact on the nature of endothelial-platelet interactions. At bottom are platelet and endothelial receptors that have been implicated in mediating interactions between these two cell types.
Abbreviations: PAF, platelet activating factor; ROS, reactive oxygen species; NO, nitric oxide; IL-1, interleukin-1; VEGF, vascular endothelial growth factor; GP, glycoprotein; PECAM-1, platelet endothelial adhesion molecule-1; ICAM-1, intercellular adhesion molecule-1; TSP-1, thrombospondin-1.
Warkentin Figure 4. Primary and secondary structure of PF4 in relation to HIT neoepitopes.
(Top) A 3-dimensional representation of the PF4 tetramer is shown, indicating the 2 neoepitope sites identified by Li et al. 6 The "ring of positive charge" formed by the lysine residues in the C-terminus of PF4 (light blue) and other lysine and arginine residues (dark blue) is also shown. (Bottom) The linear sequence of the 70-amino acid polypeptide of a single PF4 molecule is shown. Four such polypeptides combine to form the PF4 tetramer. PF4 is classified as a member of the C-X-C subfamily of chemokines because of its cysteine 10 -leucine 11 -cysteine 12 sequence. (A) Ribbon model of β 2 GPI based upon crystal structure: the protein is composed of an extended chain of 5 SCR domains having a "fishhook" appearance. The structure of SCR domain V deviates from the standard fold of the 4 other domains and forms the putative phospholipid-binding site. β-strands are shown in red and helices in green.
(B) The structural data suggest a simple membrane-binding mechanism in which the cationic patch of domain V has an affinity for anionic phospholipid. The stretch of Ser311 to Lys317 forms a hydrophobic loop that inserts into the lipid bilayer and positions Trp316 at the interface region between the acyl chains and the phosphate headgroups of the lipids, thereby anchoring the β 2 GPI in the membrane.
Current data support the hypothesis that aPL antibodies reactive against β 2 GPI mainly recognize epitopes on domains I and II and that antibody-mediated dimerization of β 2 GPI markedly increases the affinity of β 2 GPI for phospholipid.
Reprinted with permission from Bouma B, de Groot PG, van den Elsen JM, et al. Adhesion mechanism of human beta(2)-glycoprotein I to phospholipids based on its crystal structure. EMBO J. 1999;18:5166-5174.
Abbreviations: aPL, antiphospholipid; β 2 GPI, β 2-glycoprotein I; SCR, short consensus repeat.
Dainiak Figure 1 (in MacVittie et al). Energy distribution from Little Boy.
Shown are the amounts of heat, blast force, and radiation released at the hypocenter and at various distances from the hypocenter after detonation of a Uranium-235 bomb (Little Boy) on August 6, 1945, at an altitude of 580 meters. The amount of power was approximately 15 kilotons of TNT.
Rand Figure 8 (in Warkentin et al). Mechanism of lupus anticoagulant effect-role as surrogate marker.
(A) Anionic phospholipids, predominantly phosphatidylserine (negative charges), serve as potent cofactors for the assembly of 3 different coagulation complexes-the TF-VIIa complex, the IXa-VIIIa complex, and the Xa-Va complex-and thereby accelerate blood coagulation. The TF complex yields factors IXa or factor Xa; the IXa complex yields factor Xa; and the Xa formed from both of these reactions is the active enzyme in the prothrombinase complex that yields factor IIa (thrombin), which in turn cleaves fibrinogen to form fibrin.
(B) Lupus anticoagulant effect. aPL antibody-β 2 GPI complexes can prolong the coagulation times, compared with control antibodies, when there are limiting quantities of anionic phospholipid available. This effect occurs via antibody recognition of domains I or II on the β 2 GPI, which results in dimeric and pentameric IgG-and IgM-β 2 GPI complexes (such as the IgG antibody-β 2 GPI complexes shown) having high affinity for phospholipid via the cofactor's domain V. These high-affinity complexes reduce the access of coagulation factors to anionic phospholipids, thereby resulting in a "lupus anticoagulant" effect in conditions where the antibody-cofactor complexes have sufficiently high affinity.
(C) Annexin A5, in the absence of aPL antibodies, serves as a potent anticoagulant by crystallizing over the anionic phospholipid surface, shielding it from availability to bind coagulation proteins.
(D) aPL antibody-mediated disruption of annexin A5 shield. aPL-β 2 GPI complexes with high affinity for phospholipid membranes disrupt the ability of annexin A5 to form ordered crystals on the phospholipid surface. This defective crystallization results in a net increase of the amount of anionic phospholipid available for promoting coagulation reactions.
Abbreviations: aPL, antiphospholipid; β 2 GPI, β 2-glycoprotein I; TF, tissue factor. 2c.
Childs Figure 12 (in Storb et al). Allogeneic T cells identified in renal cell
